English
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
The Balancing Act, Lifetime TV’s morning program, aired a half-hour segment on IgA Nephropathy in the ‘Behind the Mystery’ program. An IgA patient and Leicester University’s Professor Jonathan Barratt discussed the disease and the challenges patients face due to lack of specifically developed treatments.
On May 18th, 2021, Calliditas Therapeutics AB (publ) (”Calliditas”) will publish its financial report for the first quarter of 2021, and at 2.30 pm CET will host a conference call to present and discuss the results.
